Condition
Malignant Neoplasms of Female Genital Organs
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 6 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
6 shownStudy of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary MetastasesNCT03093909 · 2017-11-22
RECRUITINGPembrolizumab With Intratumoral Injection of Clostridium Novyi-NTNCT03435952 · 2018-07-10
ACTIVE_NOT_RECRUITINGPneumoperitoneum Management With Low vs. Higher PressureNCT03128281 · 2018-07-01
WITHDRAWNSelumetinib and Olaparib in Solid TumorsNCT03162627 · 2017-08-04
ACTIVE_NOT_RECRUITINGLenvatinib and Capecitabine in Patients With Advanced MalignanciesNCT02915172 · 2016-12-01
WITHDRAWNFeasibility of the NEXT Steps Weight Loss Intervention +/- Resistance Training for Endometrial Cancer Survivors: Effect on Lean Mass & BiomarkersNCT02774759 · 2016-10-17
ACTIVE_NOT_RECRUITINGCommon interventions
QuestionnairesBEHAVIORAL2AccelerometerDEVICE1Aerobic ExerciseBEHAVIORAL1CapecitabineDRUG1Clostridium Novyi-NTBIOLOGICAL1ConMed AirSeal Insufflation System (AIS) at Higher PressureDEVICE1ConMed AirSeal Insufflation System (AIS) at Low PressureDEVICE1Conventional Insufflation System (CIS)DEVICE1DoxycyclineDRUG1Fitness TestBEHAVIORAL1GemcitabineDRUG1LenvatinibDRUG1OlaparibDRUG1PembrolizumabDRUG1Resistance TrainingBEHAVIORAL1SelumetinibDRUG1Telephone Coaching/Phone CallsBEHAVIORAL1Video Chat SessionsBEHAVIORAL1
Leading sponsors
Trial status mix
ACTIVE_NOT_RECRUITING3
WITHDRAWN2
RECRUITING1
Phase mix
PHASE14
NA1
PHASE21
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.